NCT03521154 · OUTCOME

Overall Survival (Count)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months

What was measured

Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause

Analysis population: Full analysis set

Groups in this outcome

Osimertinib

80mg once daily tablet

Placebo

Matching Placebo

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Osimertinib	143
Placebo	73

Reported measurements

Source class 1

Died

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Osimertinib	28	Not reported	Not reported	Not reported	Not reported
Placebo	15	Not reported	Not reported	Not reported	Not reported

Censored (includes participants still in survival follow up and terminated prior to death)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Osimertinib	115	Not reported	Not reported	Not reported	Not reported
Placebo	58	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
28
group Id
OG001
value
15
title
Died
measurements
group Id
OG000
value
115
group Id
OG001
value
58
title
Censored (includes participants still in survival follow up and terminated prior to death)

denoms

counts
group Id
OG000
value
143
group Id
OG001
value
73
units
Participants

description

Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause

groups

description
80mg once daily tablet
id
OG000
title
Osimertinib
description
Matching Placebo
id
OG001
title
Placebo

param Type

COUNT_OF_PARTICIPANTS

population Description

Full analysis set

reporting Status

POSTED

time Frame

Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months

title

Overall Survival (Count)

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice